Decreased Expression of Annexin A1 during the Progression of Cervical Neoplasia

Ld, Wang; Yh, Yang; Liu, Y; Ht, Song; Ly, Zhang; Pl, Li

doi:10.1177/147323000803600407

Cited by 29 publications

(27 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Squamous cell carcinoma of esophagus showed a significant reduction of ANXA1 mRNA and protein expression, which is strongly expressed in the normal squamous epithelium. This finding is compatible with previous studies that identified ANXA1 as a marker of differentiation in squamous cell carcinoma of the cervix, and head and neck [8-10]. Down-regulation of ANXA1 seems to be exceptional in adenocarcinomas, since many clinical cases documented overexpression in adenocarcinoma of various organs, e.g.…”

Section: Discussionsupporting

confidence: 92%

“…However, more recently, ANXA1 protein has been recognized to be differentially expressed in various human tumors, e.g., breast cancer, prostate cancer, esophageal cancer, gastric cancer, endometrial carcinoma, pancreatic cancer, and colorectal cancer [2-13]. Loss/aberrant expression pattern of ANXA1 in esophageal squamous cell carcinoma, prostate cancer, and endometrial carcinoma could be correlated with altered tumor behavior, e.g., dedifferentiation of tumor cells, increased invasiveness, and thus with tumor progression [6,8-10,12]. On the other hand, increased expression pattern of ANXA1 in hepatocellular carcinoma, colorectal cancer, and pancreatic cancer was shown to be associated with tumor growth, lymph node metastasis, and advanced disease stages, and consequently with poor patient outcome [11,13,14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Differential expression of ANXA1 in benign human gastrointestinal tissues and cancers

Gao

Chen

et al. 2014

BMC Cancer

View full text Add to dashboard Cite

BackgroundAnnexin-1 contributes to the pathological consequence and sequelae of most serious human diseases including cardiovascular disease and cancer. Although diverse roles in carcinogenesis have been postulated, its role in human gastrointestinal cancers still remains controversial.MethodsThe mRNA and protein expression profiles of ANXA1 were studied in human esophageal, gastric, pancreatic, colorectal, liver, and bile duct cancers using Real-Time PCR, western blotting, and immunohistochemistry. Gain/loss-of-function by pcDNA3.1-ANXA1 and ANXA1-shRNA was performed in gastric cancer cells.ResultsANXA1 was widely expressed in adult gastrointestinal tissue. All methods showed that ANXA1 was down-regulated in esophageal, gastric, and bile duct cancers, but up-regulated in pancreatic cancer. Forced ANXA1 expression in gastric cancer cells leads to cell growth inhibition and concomitantly modulates COX-2 expression. We confirm loss of ANXA1 and overexpression of COX-2 in clinical gastric cancer, suggesting that the anti-proliferative function of ANXA1 against COX-2 production might be lost.ConclusionsANXA1 expression is “tumor-specific” and might play a multifaceted role in cancer development and progression. ANXA1 was widely expressed in normal gastrointestinal epithelium, suggesting its role in the maintenance of cellular boundaries. Furthermore, ANXA1 regulates GC cell viability via the COX-2 pathway.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Differential expression of ANXA1 in benign human gastrointestinal tissues and cancers

Gao

Chen

et al. 2014

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Previous reports suggest that ANXA1 is involved in membrane aggregation, cell matrix interaction, vesicle transport, phagocytosis, proliferation, apoptosis, inflammation and cell transformation29. ANXA1 expression is up-regulated in breast cancer30, hepatocellular carcinoma31, melanoma32, and rectal cancer, but down regulated in nasopharyngeal carcinoma33 and cervical cancer34. In breast cancer, ANXA1 expression is associated with BRCA1/2 mutations35.…”

Section: Discussionmentioning

confidence: 99%

Identification of specific biomarkers for gastric adenocarcinoma by ITRAQ proteomic approach

Wang

Zhi

Liu

et al. 2016

Sci Rep

View full text Add to dashboard Cite

The aim of this study was to identify biomarkers for gastric cancer (GC) by iTRAQ. Using proteins extracted from a panel of 4 pairs of gastric adenocarcinoma samples (stage III-IV, Her-2 negative), we identified 10 up regulated and 9 down regulated proteins in all four pairs of GC samples compared to adjacent normal gastric tissue. The up regulated proteins are mainly involved in cell motility, while the down regulated proteins are mitochondrial enzymes involved in energy metabolism. The expression of three up regulated proteins (ANXA1, NNMT, fibulin-5) and one of the down regulated proteins (UQCRC1) was validated by Western Blot in 97 GC samples. ANXA1 was up regulated in 61.36% of stage I/II GC samples compared to matched adjacent normal gastric tissue, and its expression increased further in stage III/IV samples. Knockdown of ANXA1 by siRNA significantly inhibited GC cell migration and invasion, whereas over expression of ANXA1 promoted migration and invasion. We found decreased expression of UQCRC1 in all stages of GC samples. Our data suggest that increased cell motility and decreased mitochondrial energy metabolism are important hallmarks during the development of GC.

show abstract

“…To date, numerous reports suggest that ANXA1 is differentially expressed depending on cancer types. In fact, ANXA1 was found to be up-regulated in esophageal cancer (8), pancreatic cancer (9), skin squamous cell carcinoma (10) and colon cancer (11), and down-regulated in cervical cancer (12), oral squamous cell carcinoma (13), prostate cancer (14), breast cancer (15-17) and laryngeal squamous cell carcinoma (18). For example, high levels of ANXA1 expression were detected in approximately 40% of cases of esophageal and gastroesophageal junction adenocarcinoma and were correlated with the progression of T factor and distant metastases (8).…”

Section: Discussionmentioning

confidence: 99%

“…The functions of ANXA1 in tumor growth and development have been examined in various types of cancer, but are not clearly understood, since ANXA1 expression is differentially expressed in different cancer types, including esophageal cancer, pancreatic cancer, skin squamous cell carcinoma, colon cancer, cervical cancer, oral squamous cell carcinoma, prostate cancer, breast cancer and laryngeal squamous cell carcinoma (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18). In the present study, we investigated ANXA1 expression in gastric and colon cancer, and analyzed the relationship between anxa1 expression and clinicopathological factors and patient prognosis.…”

Section: Introductionmentioning

confidence: 99%

Up-regulated Annexin A1 expression in gastrointestinal cancer is associated with cancer invasion and lymph node metastasis

Sato

Kumamoto

Saito

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. annexin a1 (anxa1) is a calcium-dependent phospholipid-linked protein, involved in anti-inflammatory effects, regulation of cellular differentiation, proliferation and apoptosis. In the present study, we investigated the expression of anxa1 in gastric and colon cancer, and analyzed the relationship between ANXA1 expression and clinicopathological factors. anxa1 mrna expression in gastric and colon cancer tissues was not significantly changed compared to that in normal tissues. When anxa1 protein expression was evaluated by immunohistochemical staining, ANXA1 expression was observed in 76 of 135 cases of gastric cancer (56.3%), and correlations were found between ANXA1 expression and depth of wall invasion (P<0.001), lymphatic invasion (P=0.023), venous invasion (P=0.002), lymph node metastasis (P=0.001) and UICC stage (P<0.001). Disease-specific survival rate was significantly lower in cases with ANXA1 expression compared to that in cases without (P=0.0053). In colon cancer, ANXA1 expression was detected in 61 of 210 cases (29.0%) and correlations were found with gender (P=0.038), lymphatic invasion (P=0.011), venous invasion (P=0.023), lymph node metastasis (P=0.042) and UICC stage (P=0.041). The disease-specific survival rate tended to be lower in cases with ANXA1 expression, although the differences were not statistically significant (P=0.6984). Our results indicate that up-regulated ANXA1 expression is involved in cancer invasion and lymph node metastasis. Furthermore, high levels of anxa1 expression were implicated in poor prognosis of patients. ANXA1 may be applicable as a prognostic biomarker in gastric and colon cancer, and a potential target for treatment.

show abstract

Decreased Expression of Annexin A1 during the Progression of Cervical Neoplasia

Cited by 29 publications

References 24 publications

Differential expression of ANXA1 in benign human gastrointestinal tissues and cancers

Differential expression of ANXA1 in benign human gastrointestinal tissues and cancers

Identification of specific biomarkers for gastric adenocarcinoma by ITRAQ proteomic approach

Up-regulated Annexin A1 expression in gastrointestinal cancer is associated with cancer invasion and lymph node metastasis

Contact Info

Product

Resources

About